



# JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3<sup>rd</sup> Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,  
Haryana (India)

Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com  
CIN NO. L74899DL1978PLC009181

November 03, 2023

The Department of Corporate Services- Listing <b>BSE Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 <b>Scrip Code: 507789</b>	The Department of Corporate Services- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 <b>Symbol: JAGSNPHARM</b>
---	--

**Subject: Outcome of Board Meeting held on November 3, 2023**  
**Proposed divestment of Company's Faridabad facility**

Dear Sir/ Madam,

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved in principle, divestment of Company's Faridabad facility. The said facility has not been operational, and proposed sale will not have any effect on the Company operations.

Disclosure as required under Regulation 30 of SEBI LODR read with Schedule III, Part A. A.1 will be provided when a binding agreement is entered into for the proposed sale.

The Board Meeting commenced at 12:45 P.M. and concluded at 13:40 P.M. hours.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

**Abhishek Joshi**  
**Company Secretary & Compliance Officer**